HRS5685
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 14, 2022
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral HRS5685 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=64 | Not yet recruiting | Sponsor: RetroLead (Shanghai) BioPharma Co., Ltd.
New P1 trial • Human Immunodeficiency Virus • Immunology • Infectious Disease
1 to 1
Of
1
Go to page
1